|
The altered structure of proteins or multimeric protein complexes underlies the mechanism of many diseases and is the focus of intense activity in medicine and drug discovery. Currently, there are no assay platforms that can easily detect and measure modified proteins and protein complexes, particularly in intact cells and tissues such as tumor biopsies. Such assessment is critical because understanding protein function in the cellular or tissue environment is the most direct means of insight into health and disease.
Ensemble's Biodetection Programs are aimed at cancer diagnosis and treatment prediction:
The BCR/ABL Program, sponsored by The Leukemia and Lymphoma Society, is developing reagents to detect and isolate cells carrying the abnormal fusion protein BCR/ABL, which is the cause of the cancer Chronic Myelogenous Leukemia (CML). >> Learn More
The ERBB Detection Program is developing reagents to distinguish between different protein dimers of the ERBB family of receptor tyrosine kinases, both homodimers and heterodimers. This family of receptors is important in breast cancer and other cancers such as colon, prostate, lung, ovary and brain. It is one of the most actively targeted families of receptors in modern oncology practice. >> Learn More
[ ]
|
